Liminatus Pharma LIMN
NASDAQ LIMN
$3.91 -0.36 (-8.43%)
At close: Sep 29, 2026 · 4:00 PM EDT

Liminatus Pharma (LIMN) Common Equity (2024 - 2026)

Updated

Liminatus Pharma's Common Equity came in at $300,612 for Q2 2026, compared with -$8.81 million a year earlier.

Analysis

Liminatus Pharma (LIMN) Common Equity (2024 - 2026) Analysis & Trends

At the end of FY2025, Liminatus Pharma's Common Equity was -$9.81 million.

  • Going back by year, Common Equity was -$19.34 million in FY2024.
  • The Q2 2026 figure represents the highest quarterly Common Equity in data going back to Q2 2024.
  • Business Quant data shows LIMN's Common Equity at -$132,596 (Q1 2026), -$9.81 million (Q4 2025) and -$1.65 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 84.97 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -5.94 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 41.98 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 41.95 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 50.37 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 11.69 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 11.83 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 85.49 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 20.25 Bn
10 Liminatus Pharma 4.78 Mn 4.78 Mn - 300,612.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 300,612.00
Mar 31, 2026 -132,596.00
Dec 31, 2025 -9.81 Mn
Sep 30, 2025 -1.65 Mn
Jun 30, 2025 -8.81 Mn
Mar 31, 2025 -19.67 Mn
Dec 31, 2024 -19.34 Mn
Sep 30, 2024 -19.11 Mn
Jun 30, 2024 -18.51 Mn
API Access

Liminatus Pharma Common Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=common-equity&ticker=LIMN&period=max&api_key=YOUR_API_KEY